SCHEMBL3472209

SCHEMBL3472209

CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(=O)NCc4ccc(C(F)(F)F)cc4)nn3-c3ccccc3Cl)s2)c1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXRA P19793 7/20 0.67
NR1H2 P55055 7/20 0.67
NR1H3 Q13133 7/20 0.67
IDH1 O75874 1/20 0.46
RORC P51449 1/20 0.41
EPHX2 P34913 2/20 0.41
KCNQ3 O43525 2/20 0.40
KCNQ2 O43526 2/20 0.40
CACNA1G O43497 1/20 0.40
CACNA1H O95180 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
LPAR5 Q9H1C0 1/20 0.40
PDE2A O00408 1/20 0.40
ELANE P08246 2/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472831 0.93 RXRA (0.66) RXRANR1H2NR1H3EPHX2KCNQ3
SCHEMBL3472414 0.92 RXRA (0.70) RXRANR1H2NR1H3IDH1CACNA1G
SCHEMBL3470711 0.90 RXRA (0.68) RXRANR1H2NR1H3EPHX2CACNA1G
SCHEMBL3473251 0.90 RXRA (0.72) RXRANR1H2NR1H3CACNA1GCACNA1H
SCHEMBL3470791 0.88 RXRA (0.73) RXRANR1H2NR1H3EPHX2CACNA1G
SCHEMBL3471059 0.87 RXRA (0.68) RXRANR1H2NR1H3CACNA1GCACNA1H
SCHEMBL3474320 0.87 RXRA (0.70) RXRANR1H2NR1H3PPARA
SCHEMBL3472973 0.87 NR1H2 (0.77) RXRANR1H2NR1H3CACNA1GCACNA1H
SCHEMBL3472477 0.86 RXRA (0.71) RXRANR1H2NR1H3MAPK8MAPK9
SCHEMBL14624827 0.86 RXRA (0.75) RXRANR1H2NR1H3EPHX2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.